WO2019215276A1 - Complément alimentaire et son utilisation pour animaux aquatiques - Google Patents

Complément alimentaire et son utilisation pour animaux aquatiques Download PDF

Info

Publication number
WO2019215276A1
WO2019215276A1 PCT/EP2019/061906 EP2019061906W WO2019215276A1 WO 2019215276 A1 WO2019215276 A1 WO 2019215276A1 EP 2019061906 W EP2019061906 W EP 2019061906W WO 2019215276 A1 WO2019215276 A1 WO 2019215276A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
feed
ppm
beta
glucan
Prior art date
Application number
PCT/EP2019/061906
Other languages
English (en)
Inventor
Rutchanee CHOTIKACHINDA
Zuoyong LUO
Thiago SOLIGO
Viviane VERLHAC
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of WO2019215276A1 publication Critical patent/WO2019215276A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/153—Nucleic acids; Hydrolysis products or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs

Definitions

  • the present invention relates to feed supplements comprising vitamin E, vitamin C, beta- Glucan and nucleotides and the use of such supplements for improving performance and health of aquatic animals including fish and shrimp, especially for cold water fish as for ex ample salmon, bream, bass and for warm water fish as for example carp, tilapia, catfish.
  • this invention relates to the use of the at least four substances as defined above for the improvement of the body length, feed conversion ratio, growth rate and/or daily weight gain in fish and shrimp, for reducing mortality by regulating the micro flora of the gut of the animal and/or by protecting the animal against infections caused by pathogen ic microorganisms.
  • the present invention also relates to the use of the at lest four substances as defined above for enhancing immunity of aquatic animals including fish and shrimp, especially for cold wa ter fish as for example salmon, bream, bass and for warm water fish as for example carp, ti lapia, catfish.
  • the present invention relates to a novel fish feed composition
  • a novel fish feed composition comprising as active ingredients vitamin C, vitamin E, beta-Glucan and nucleotides derived from natural sources.
  • feed or feed composition means any compound, preparation, mixture, or composi- tion suitable for, or intended for intake by an animal.
  • Turnover rate is determined by how fast the fish grow to a harvestable size. As an example, it takes from 12 to 18 months to raise Atlantic salmon from smolt (the physiological stage when the Atlantic salmon can first be transferred from fresh water to sea water) to harvestable size. A fast turnover has several positive results. First, it helps cash flow. Second, it improves risk management. Es pecially, a high mortality rate is a substantial risk for fish farmers.
  • the inventors of the present application surprisingly found that substances as defined above have a great potential for use in shrimps and fish feed, e.g. for improving the body length, feed conversion ratio, growth rate and/or daily weight gain and in particular for reducing mortality and for enhancing immunity. Further, the inventors surprisingly found that the substances, which are hereinafter also referred to as compounds, have also antimicrobial ac tivity resulting in a reduced mortality.
  • the unique selection of active compounds of the pre sent invention allows for the first time controlling a number of fish and shrimp diseases caused by a number of different pathogens.
  • the invention relates to methods for using the combination of vitamin E, vitamin C, beta-Glucan and nucleotides in shrimps and fish feed for improving the body length, feed conversion ratio, growth rate and/or daily weight gain and/or for reducing mortality by preventing diseases caused by pathogenic microorganisms and/or for enhancing immunity.
  • selected compounds of the invention exhibit excellent effects inhibiting the growth of marine strains, such as Vibrio parahaemolyticus, vibrio harveyi, vibrio anguillarum, Yersinia ruckeri or Vibrio haemolyt- icus which causes Acute Hepatopancreatic Necrosis Disease (AHPND) found especially in shrimps and causing high mortality.
  • marine strains such as Vibrio parahaemolyticus, vibrio harveyi, vibrio anguillarum, Yersinia ruckeri or Vibrio haemolyt- icus which causes Acute Hepatopancreatic Necrosis Disease (AHPND) found especially in shrimps and causing high mortality.
  • AHPND Acute Hepatopancreatic Necrosis Disease
  • feed additive compositions as hereinafter defined improves immune status, growth and feed conversion of shrimps.
  • the feed additive composition according to the present invention comprises
  • vitamin C added for example as ROVIMIX ® STAY-C ® 35 (DSM Nutritional Prod ucts, Switzerland) which is at 35% vitamin C
  • vitamin E added as ROVIMIX ® E50 (DSM Nutritional Products, Switzerland) which is 50% vitamin E
  • nucleotide mixture derived from a natural source (for example ROVIMAX ® NX plus from DSM Nutritional Products, Switzerland)
  • the inventors have been able to demonstrate that a mixture of these active ingredients used in synergy and in combination exhibits, in totally unexpected manner, the effects sought by the present invention of improving digestibility, growth and bone development and of boost ing the immune system of shrimps.
  • body length, growth rate, weight gain and feed conversion ratio can be improved in fish and shrimps by administering to the animals an ef fective amount of a feed supplement composition consisting vitamin C, vitamin E, beta- glucan and nucleotides.
  • feed conversion ratio is determined on the basis of a growth trial comprising a first treatment in which the composition according to the invention is added to the animal feed in a suitable concentration per kg feed, and a second treatment (control) with no addition of the composition to the animal feed.
  • an improved FCR is lower than the control FCR.
  • the FCR is improved (i.e. reduced) as compared to the control by at least 1.0% or 5%.
  • the term“mortality” as used herein refers to the ratio of life animals at the end of the growth phase versus the number of animals originally included into the pond. It may be determined on the basis of a fish challenge trial comprising two groups of fish challenged by a particular fish pathogen with the aim to provoke a mortality of 40 to 80% of the animals in the untreated group. However, in the challenge group fed with a suitable concentration per Kg of feed of a mixture of at least two compounds according to the invention, the mortality is reduced compared to the untreated group by at least 5%, preferably at least, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or at least 50%.
  • immunosens as used herein is characterized by total phenoloxidase activities (U/mg), serum bactericidal activities (Ua), lysozyme activities, expression of immune genes
  • Enhancing immunity means the increase of the activities of the enzymes, the increase of the genes expression, and or the increase of Haemocyte and/or granulocyte counts.
  • Fig. 1 shows immune gens expression of Shrimps with different DSM health premix on 4th and 8th week: (A) 4th week, (B) 8th week.
  • Fig. 2 shows the cumulative mortality rate of shrimp challenged with Vibrio.
  • Fig. 3 shows the cumulative mortality of whiteleg shrimp fed the three different DSM diets and then challenged with a pathogenic strain of Vibrio parahaemolyticus. The shrimp were monitored every three hours until the experiment was terminated 187 hours post-infection.
  • the inventors of the present application surprisingly found that the compounds according to the invention and mixtures thereof are effective against a number of pathogenic microorganisms of cold and warm water fish.
  • Compositions according to the invention were shown to exhibit inhibitory effect against Vibrio anguillarum, a shrimp pathogen causing vibriosis.
  • Compositions according to the invention were shown to exhibit inhibitory effect against Aeromonas salmonicida which is the pathogen causing a disease known as furunculosis.
  • Compositions according to the invention were shown to exhibit inhibitory effect against Edwardsellia tarda causing systemic infection in fish.
  • compositions according to the invention were shown to exhibit inhibitory effect against Lactococcus garvieae which is the etiological agent of Latococcosis, an emergent disease which affects many fish species and causes important economic losses both in marine and freshwater aquaculture when water temperature increases over l6°C in summer months.
  • compositions according to the invention exhibit excellent inhibitory effects on the growth of Yersinia ruckeri, a pathogenic microorganism which causes Enteric Redmouth (ERM), a disease found especially in salmonids.
  • ERM Enteric Redmouth
  • Vibrio salmonicida which is a psychrophilic bacterium that is the causative agent of cold-water vibriosis in Atlantic salmon.
  • Aeromonas hydrophila causing ulcers and hemorrhagic septicaemia. This patho gen is very resistant to conventional simple antimicrobials like chlorine.
  • Photobacterium damselae, formerly Pasteurella piscicida a pathogen causing high losses in the culture industry of economically important marine fishes such as seriola and red grouper in Japan and striped bass and white perch in the United States.
  • Vibrio harveyi responsible for luminous vibriosis, a disease that affects commer cially-farmed prawns
  • vitamins E and C are commercially available or can easily be prepared by a skilled per son using processes and methods well-known in the prior art.
  • vitamin E is available under the Trademark ROVIMIX ® E50 (DSM Nutritional Products, Switzerland), vitamin C under the Trademark ROVIMIX ® STAY-C ® (DSM Nutritional Products, Swit zerland).
  • Beta-glucan may be obtained from any source, and a composition thereof may be prepared using convenient technology selenium.
  • a preferred commercially available product is Leiber ® beta-S plus (Leiber GmbH, Germany), a product comprising beta-l,3-l,6 glucan.
  • a mixture of nucleotides according to the invention is commercially available (for example under the Trademark ROVIMAX ® NX, supplied by DSM Nutritional Products, Kaiseraugst, Switzerland) or can easily be prepared from a yeast source by a skilled person using pro- Deads and methods well-known in the prior art.
  • this invention relates to the use of composition consisting vitamin C, vita min E, beta-glucan and nucleotides for improving body length, feed intake, weight gain, feed conversion ratio, growth rate and/or bone development in fish and shrimps and for boosting the immune system of the animals.
  • This aspect encompasses also a method of feeding of an animal with a feed supplement composition
  • a feed supplement composition comprising as main ingredients composition consisting vitamin C, vitamin E, beta-glucan and nucleotides.
  • Vitamin C, vitamin E, beta-glucan and nucleotides are suitably administered together with the feed.
  • feed or feed composition means any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal.
  • feed as used herein comprises both solid and liquid feed as well as drinking fluids such as drinking water.
  • the combination of ingredients according to the invention can be added as a formulated feed supplement composition directly to the regular animal feed or to a premix containing other vitamins, minerals, amino acids and trace elements which is added to regu lar animal feed and thorough mixing to achieve even distribution therein.
  • a feed supplement composition which comprises vitamin C, vitamin E, beta-glucan and nucleotides.
  • a preferred feed supplement composition comprises vitamin C, vitamin E, beta-glucan and nucleotides in amounts sufficient to reach the following concentrations in the final feed: from about 500 to 2000, preferably 1000 ppm vitamin C
  • a more preferred feed supplement composition comprises:
  • a third aspect of the invention relates to a premix or regular animal feed which comprises a feed supplement composition according to the invention.
  • the incorporation of the feed supplement composition as exemplified herein above to fish or shrimps feed is in practice carried out using a concentrate or a premix.
  • a premix desig nates a preferably uniform mixture of one or more micro-ingredients with diluent and/or carrier. Premixes are used to facilitate uniform dispersion of micro-ingredients in a larger mix.
  • a premix can be added to feed ingredients or to the drinking water as solids (for ex ample as water soluble powder) or liquids.
  • feed-additive ingredients are aroma compounds; stabilisers; antimicrobial peptides; polyunsaturated fatty acids (PUFAs); reactive oxygen generating species; and/or at least one enzyme selected from amongst phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4., phospholipase Al (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (EC 3.1.4.3); phospholipase D (EC 3.1.4.4); amylase such as, for example, alpha-amylase (EC 3.2.1.1); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6).
  • PUFAs polyunsatur
  • antimicrobial peptides examples include CAP18, Leucocin A, Protegrin-l, Thanatin, Defensin, Lactoferrin, Lactoferricin, and Ovispirin such as Novispirin (Robert Lehrer, 2000), Plectasins, and Statins.
  • polyunsaturated fatty acids examples include g, C 2 o and C 22 polyunsaturated fatty acids, such as arachidonic acid, docosohexaenoic acid, eicosapentaenoic acid and gamma-linoleic acid.
  • reactive oxygen generating species are chemicals such as perborate, persul phate, or percarbonate; and enzymes such as an oxidase, an oxygenase or a syntethase.
  • fat- and water-soluble vitamins, as well as trace minerals form part of a so-called premix intended for addition to the feed, whereas macro minerals are usually separately added to the feed.
  • a premix can contain, for example, per ton of fish feed, 50 to 200g of a propylene glycol solution of the mixture of the active compounds, 20 to lOOOg of an emulsifying agent, 50 to 900g of cereals and by-products, 20 to lOOg of a proteinic support (milk powder, casein, etc.) and 50 to 300g of a mineral component (expanded silica, feed quality lime, bi-calcium phosphate, etc.).
  • the experimental diets were composed according to Table 1.
  • the experimental products were added to the diet at the concentrations described in Table 2 and homogenised thor- oughly.
  • the weight of the experimental products was subtracted from the weight of Sepio- lite (inert).
  • Treatment A which was considered to be the control diet, was supplemented with ROVIMIX® STAY-C® 35 experimental product.
  • Penaeus vannamei were imported as postlarvae (PLs) from Shrimp Improvement Systems, Florida, USA. These shrimps were certified to be specific pathogen free (SPF) for the fol lowing pathogens: WSSV, YHV/GAV/LOV, TSV, IHHNV, BP, MBV, BMN, IMN, Mi- crosporidians, Haplosporidians and NHP bacteria.
  • SPF pathogen free
  • shrimp PLs were transported to the facilities and reared in a water recircula tion system containing artificial seawater at a salinity of 20 g L 1 . They were raised on an ar tificial diet (replacement for alive feed) and after weaned onto a pelleted feed.
  • the Vibrio Parahaemolyticus strain TW01 was isolated from Acute Hepatopancreatic Ne crosis Disease (AHPND) infected shrimp ponds and characterised in laboratory. Stocks of all bacteria are permanently kept frozen at -70°C at the facilities. After thawing, the stocks will be aseptically and separately inoculated in culture medium and grown using standard conditions. The optical density of the resulting bacterial suspensions will be determined spectrophotometrically. These data will be used to determine the concentration of bacteria in the suspension in colony forming units per millilitre (CFU/ml).
  • AHPND Acute Hepatopancreatic Ne crosis Disease
  • Plastic tanks with a capacity of 290L feeding units are filled with artificial seawater com posed by adding a commercial sea salt mixture to purified water at 20 g L 1 .
  • Each tank is equipped with an individual filtration system composed by a protein skimmer, a mechanical filter and a biological filter.
  • the biological filter is supplied with a given volume of filtration media, which was previ ously colonized with nitrifying bacteria.
  • the total weight of the groups is taken at the beginning and every 7 days until the end of the trial.
  • the shrimp’s mean body weight (MBW) is calculated at the beginning of the trial for each group.
  • the daily feeding rate for each group is calculated based on shrimp’s MBW (standard feeding percentages per weight) and adjusted daily according to the expected shrimp growth and mortality. This is corrected weekly after weighing the groups.
  • the feed distribution is done automatically 6 times a day.
  • a total of 600 shrimp with a mean body weight (MBW) of 0.4 g were used to randomly compose 12 groups of 50 individuals. Each group was housed in one feeding unit.
  • MMW mean body weight
  • Each experimental diet was randomly assigned to 3 tanks according to the setup described in Table 3.
  • the groups of shrimp received the respective di ets at the predetermined percentages of their initial MBW and expected daily growth.
  • the groups were weighed at the start, 7, 14, 21 and 28 days.
  • the feeding period served a double purpose, to roughly evaluate the growth performance of the shrimp and to prepare them for disease challenge by allowing the products to induce their putative effect and an adaptation of the animal’s organism to the experimental prod- ucts. This eventually maximised the assumed protection against AHPND.
  • the growth performance was assessed by the following parameters:
  • the shrimp are housed individually in 10L glass tanks (infection units) filled with artificial seawater.
  • the seawater is composed by adding a commercial salt mixture to purified water at 20 g L- 1 .
  • the tanks are equipped with an individual mechanical/biological filter.
  • the filters are supplied with filtration media previously colonized with nitrifying bacteria.
  • the dietary treatment replicates correspond to 3 blocks of 10 individual shrimp per treat ment (in total 30 shrimp individually housed).
  • the 3 blocks are placed at a different loca- tion of the challenge setup. This is carried out in order to account for possible variations induced by the location (light and temperature) within the setup. For purposes of statisti cal analysis, all shrimp are taken as housed individually.
  • Each shrimp is labelled as small, medium or big due to normal size variation in these ani mals. This categorization is made visually. The weight correspondent to each category will be determined by individually weighing 50 random shrimp. This information is used to determine the amount of feed that each shrimp receives per day.
  • the setup is maintained daily. Seven days before the main AHPND challenge, we performed a pre-challenge aiming at ad justing the Vibrio parahaemolyticus strain dose necessary to induce a final mortality of 50- 80% in the specific shrimp batch used in this trial. A dose of 4* 10 5 CFU/ml was determined during the pre-challenge and subsequently used in the main AHPND challenge.
  • shrimp were transferred from the feeding trial facility to the disease challenge facility and housed in the infection units (1 shrimp per tank) for acclimatization.
  • Shrimp from each feeding group replicate were used to compose a certain amount of infection units, according to the setup in Table 3.
  • each tank was inoculated (in water) with the dose pre-determined for each trial, as above described.
  • One hour after inoculation each shrimp received the first portion of the respective experimental diet. This procedure was specially designed to maximise the interac tion of the experimental products with the disease and ensure that the experimental products (or its effect) were present in the shrimp organism at the highest level possible during the critical moments of infection.
  • the clinical outcome will be evaluated by the following parameters:
  • the mortality outcome in each feed treatment group was statistically compared with the control treatment group using a custom-made statistical methodology.
  • the dimensioning of this challenge test was set to detect significant differences (treatment groups versus control groups) for survival improvements equal or higher than 25%.
  • Table 3 Overview of the experimental setup used for AHPND challenge with previous feed adaption period.
  • the feeding trial was executed according to the protocol described in the materials and methods section. No technical problems were encountered during the procedure. All the evaluated parameters were within the ranges normally observed in our feeding sys tem.
  • Table 4 Overview of the results of the growth performance parameters recorded during the feeding trial. Values are presented as average ⁇ standard deviation. Values sharing the same label are not significantly different from each other tp>0.05 ). Values that have no label in common are significantly different from each other (p ⁇ 0 05). Significant differences were found between dietary treatments for SGR and FCR.
  • the disease challenge was executed according to the standard procedure described in the materials and methods section and no problems were encountered during its execution.
  • Control group positive control for disease
  • ROVIMIX® STAY- C® 35 an experimental product ROVIMIX® STAY- C® 35.
  • the expected range of 50-80% mortality is normally reached.
  • the current control feed behaved similarly.
  • the mortality levels of the Mock (negative control for disease) group was 0% (Table 5), which demonstrates the correct exe cution of the experiment.
  • Table 5 Overview of the results recorded during the challenge with Vibrio parahaemolvti- cus. Values are presented as average of 3 dietary treatment replicates ⁇ standard deviation Values sharing the same label are not significantly different from each other (p>0 05). Val ues that have no label in common are significantly different from each other tp ⁇ 0.05 ). Sig nificant differences were found between dietary treatments for final mortality.
  • the mortality level was 43%, 33%, 20% and 47% for A, B(RSC-RE50), C (RSC-RE50-LBS+-RNX+) and D (RSC-ALA) treatments.
  • B(RSC-RE50) the mortality re mained lowest in treatments B and C, namely 57% and 44%, whereas A and D reached al ready 70% and 87% mortality.
  • treatment C (RSC-RE50-LBS+-RNX+) performed very well with significantly lower (and delayed) mortality compared to all other treatments, namely 64,4% (C) versus 90-93% (A, B and D).
  • the feeding trial was performed at an indoor industrial shrimp farm in Shandong Yellow River Delta Ocean Sci-Tech Co., Ltd. (Dongying, Shandong, China). An eight-week growth trial was carried out from November 2017 to January 2018. After 20 days of nurse ry, Pacific white shrimps postlarvae 25 (PL25) were moved to grow-out tanks.
  • Shrimps (PL 25, 0. l7g, initial weight)) were randomly distributed into nine concrete tanks (38m 2 ) in greenhouse with 27000 shrimps per tank (stocking density: 710 shrimp/m 2 ). Concrete tanks were equipped with water exchange system receiving a constant supply of filtrated seawater and uninterrupted oxygenation system.
  • DSM Health Premix comprised:
  • ROVIMIX® STAY-C® 35 which is at 35% vitamin C 800 ppm vitamin E added as ROVIMIX® E50 which is 50% vitamin E
  • beta-glucan as Leiber ® beta-S plus
  • Shrimp from nine treatment groups were fed four times daily at the satiation rate according to standard feeding rate. Feeding rate was adjusted according to shrimp weight through the 60 days experimental period. Water temperature (27-30 °C), pH (7.8-8.3), salinity (35 ppt), dissolved oxygen (5.3-6.1 mg L 1 ), ammonia-nitrogen (0.10-0.30 mg L 1 ), and nitrite- nitrogen (0.03-0.10 mg L 1 ) were determined daily throughout growth trial. In order to as sess the growth performance of shrimps in all the tank, approximately 30 shrimps from each replicates of group were sampled randomly on 4th and 8th week to measure individual weight. Mean final weight, and specific growth rates were determined.
  • Hae molymph was collected from the ventral sinus cavity of shrimp using 1 mL tuberculin sy- ringe (26 gauge) containing chilled (4°C) anticoagulant solution (10 mM EDTA-Na2, 450 mM NaCl, 10 mM KC1, 10 mM HEPES, pH 7.3) at a proportion of one part hemo lymph to three parts anticoagulant solution.
  • Haemolymph was centrifuged at 3 000 rpm for 10 min at 4°C, supernatant was used for determination of enzyme activity, hemocyte pellet will be rinsed twice and used for determination of immune-related genes expression.
  • Total phenoloxidase activity was determined by using L-DOPA as substrate. Briefly, 100 m ⁇ of centrifuged haemolymph was mixed with 50 m ⁇ PBS solution and 50 m ⁇ of enzyme inducer trypsin (Hi Media, 1 mg ml 1 ) and incubated for 15 min at 25°C in 96-microliter plates. In controls, trypsin and serum was replaced by PBS. After incubation, 100 m 1 of a L-DOPA solution (lOmg lml 1 ) was added to that mixture and incubated for 10 min at 25°C. Then the sample was read at 490nm using a microplate reader.
  • One unit of serum antibacterial ac tivity was defined as a difference of 0.01 between R (control) and R (treatment), where R represents the ratio of change in bacterial counts from the beginning and end of the reac tions and calculated as: where, A 0 and A t are the bacterial counts at the beginning and end of the reactions, respec tively.
  • Lysozyme activity was measured by the modified method. In this turbidometric assay, 0.03% lyophilized Micrococcus lysodeikticus in PBS was used as substrate. Ten microlitres of haemolymph were added to 250 m 1 of bacterial suspension in duplicate wells of a micro- titre plate and the reduction in absorbance at 490 nm was determined after every minutes (1, 2, 3, 4 and 5) of incubation at 22°C using a microtiter plate reader. One unit of lysozyme activity was defined as a reduction in absorbance of 0.001 per min.
  • First strand cDNA was generated with 20ul reaction volume containing 2mg total RNA, l x RT buffer, lmM dNTP, 0.2 mM Oli- go(dTl5), 10U of RNase inhibitor and 50U Multi-Scribe Reverse Transcriptase (Applied Biosystems) and the reaction was conducted at 37°C for 2 h.
  • Gene expression was analyzed by quantitative real-time PCR (qPCR) using Bio-Rad CFX384 (Bio-Rad Laboratories, Richmond, CA) using SYBR Green Supermix kits. 3 im mune-related genes commonly found in shrimp were selected for the analysis of expression levels: prophenoloxidase (proPO), penaeidin-3 (PEN), lysozyme (LSZ). The qPCR condi tions were 95 °C for 3 min and 50 cycles of 95°C for 10 s and 58 °C for 30 s. Relative gene expression was calculated as 2_DDCT, where Ct is threshold cycle. The expression levels of the housekeeping gene beta-actin were not altered with any of call population (data not shown). Data was be analyzed by one way ANOVA with post hoc LSD to adjust P values for multiple comparisons. P ⁇ 0.05 was considered statistically significant.
  • the isolated bacterial pathogen Vibrio parahaemolyticus was used as a test organism.
  • the bacterial strain VP1 was subcultured and centrifuged at lOOOOg for 10 minutes at 4°C. The supernatant was discarded and the bacterial pellet was washed three times and resuspended in phosphate buffered saline (PBS) at pH 7.4.
  • PBS phosphate buffered saline
  • infection dosage of 10 8 cfu/ml was determined.
  • the Vibrio doses, in immersion-route groups, were produced by dilution of bacteria in sterile seawater to 10 8 cfu/ml. All shrimps were monitored after Vibrio infection. The experiment last for 3 days. Shrimps were continued feeding with the corresponding diets twice daily after challenge. The survival rate was recorded and calculat- ed.
  • Table 7 The weight with different DSM health premix of shrimps on 4th week and 8th week
  • Table 8 The weight with different DSM health premix of shrimps in every week lth 2nd 3rd 4th 5 th 6th 7th 8th
  • the immunological parameters were measured on 4th and 8th week of the feeding trial.
  • Shrimp fed 0.5% DSM health premix and 0.8% DSM health premix had a significantly higher immune response (p ⁇ 0.05), including Total phenoloxidase (PO) activity, Serum anti bacterial activity and Lysozyme activity, compared with the control group (Table 10).
  • Shrimp fed 0.5% DSM health premix had higher PO, Serum antibacterial and Lysozyme activity than the control group but less pronounced than the 0.8% DSM health premix.
  • Table 10 Dietary effect of DSM health premix on immunological parameters ofshrimp on 4th and 8th week immunological pa 4th week 8th week
  • the expression ratio of target immune genes (proPO, PEN-3 and LSZ) of the haemocytes of shrimp fed with 0.5% DSM health premix and 0.8% DSM health premix is shown in Fig. 1. Dietary inclusion of DSM health premix significantly enhanced the mRNA expressions of immune genes on 4th and 8th week (P ⁇ 0.05) when compared with DSM health premix and control diet groups at all the time points tested throughout the experimental period. The immune genes expression was no significantly different (P ⁇ 0.05) on the 4th week between fed 0.5% DSM health premix and 0.8% DSM health premix group.
  • DSM health premix enhances regulation of the immune effector mechanisms in P. vannamei by increasing the expression of immune genes. A dose dependent increase in the expression of immune genes was observed in the DSM health premix diet fed groups.
  • DSM health premix showed lower cumulative mortality rate (65%) . Therefore, in the immersion challenge shrimp supplemented with 0.5% DSM health premix and 0.8% DSM health premix showed a slower mortality initially compared to control.
  • the DSM health premix feed additive products can enhance the immunity of shrimp and upregulated the expression of immune genes.
  • the DSM health premix also can be used as a potential supplemented diet in shrimp culture system with the view of enhancing the immune status of shrimp.
  • the whiteleg shrimp ( Penaeus vannamei ) used for the trial were acquired as post-larvae (PL stage 14) from a specific pathogen free (SPF) hatchery supplied through Charoen Pok- phand.
  • SPF pathogen free
  • a subsample of 150 PL split into 10 x 10-15 samples were selected at random and fixed in 95% ethanol and then submitted for disease testing.
  • the shrimp were screened for AHPND, EHP, IHHNV, IMNV, TSV, WSSV and YHV and were found to be negative for all diseases.
  • the PL were then nursed in ca. 30°C, bio floe, 15 ppt water at a stocking density of ca. 9 PL L 1 and fed ad libitum a commercial pelleted feed until they reached an average weight of ca 1.0 g.
  • Diets 1, 2 and 3 were prepared with or without the product Health Boost according to table 11 and the stability of these in water and the acceptability to shrimp were tested.
  • the Health boost comprises:
  • ROVIMIX® STAY-C® 35 which is at 35% vitamin C
  • beta-glucan as Leiber ® beta-S plus
  • Table 11 Ingredients and content of diets 1 GP ). 2 (T2) and 3 (T3)
  • the shrimp were then graded and allocated in batches of 25 animals to each experimental tank. A total of 16 replicates per dietary group were requested but an extra tank per diet was added. In addition, a further five tanks were added to the design to appraise the accep- tibility of the DSM experimental diets to a commercial brand of shrimp feed; for the current trial CP Starbird was used.
  • the inclusion of the CP Starbird feed was not to directly test and compare the growth per formance of the shrimp fed this diet but was added to ensure the shrimp consumed the ex perimental diets.
  • the starting weights of the shrimp allocated to each tank were then subjected to an ANOVA and Tukey post-hoc tests to ensure that there were no significant differences between dietary groups.
  • the shrimp in each tank were fed five times a day at 08.00 am, 11.00 am, 14.00 pm, 17.00 pm and 21.00 pm hours.
  • the feed was placed in submerged feeding trays and the shrimp will be given two hours to feed on the diet after which the trays were removed.
  • Uneaten feed pellets at each meal were counted and then stored at -80°C for subsequent dry matter analysis by the study monitor.
  • Table 12 A summary of shrimp performance following the 21 -day feeding period on the
  • DSM experimental diets The average final weight, total biomass, survival and growth met rics of each dietary group are presented.
  • ADG average daily growth rate
  • AGR average growth rate
  • FCR food conversion ratio.
  • DSM Diet 2 differed significantly from the other diets in terms of the average weight of the shrimp at the end of the 21 -day feeding pe- riod, the total biomass was also higher, as was the survival of the shrimp (i.e. 92.9% com pared to 88.7% for Diet 3 the next best peforming diet in terms of survival).
  • Vp Vibrio parahaemolyticus
  • Representative whiteleg shrimp from each diet were allocated to the 20 L chal- lenge tanks. Each tank was sub-divided into 10 equal sized sections by sterile future board dividers. 15 tanks were used for each diet, i.e. a total of 45 tanks were set-up. Mesh cov ered panels were inserted into each side wall to allow for the free movement of bacteria be tween compartments. The tanks were filled with 7.5 L pre-treated, dechlorinated, 15 ppt seawater and maintained at 29°C degrees within a temperature controlled room within the Fish Vet Group Challenge Facility. A single shrimp was placed in each section.
  • the inoculum for the challenge trial was prepared by inoculating the fpAHPND isolate FVG0001 into tryptone soya broth (TSB) supplemented with 2% NaCl and culturing for 12 h at 28°C with shaking (ca. 250 rpm). Bacterial cells were collected by centrifugation at 900 xg for 10 min at l0°C and then the bacterial pellet was re-suspended in sterile 15 ppt sea water. The number of colony- forming units (CFU) mL 1 in the suspension was estimated by measuring the optical density at 600 nm (OD600), as an OD600 of 1.0 equated to ca. 1.0x 108 CFU mL 1 .
  • OD600 optical density at 600 nm
  • the suspension was adjusted to the desired OD600 with sterile 15 ppt seawater, and then CFU mL 1 verified by diluting and plating suspensions across tryptone soya agar and incubating at 28°C until CFU could be enumerated.
  • the quantity of bacteria required for each challenge was determined from virulence pre-tests performed typically ⁇ 48 h earlier to the main challenge. Each virulence pre-test was conducted on shrimp from the same population intended for use in the trial and under the same conditions as the actual challenge. The pre-tests used a minimum of three bacterial concentrations and three individ ually-housed shrimp per dose to determine the CFU mL-l required to give a ca. 66% mor tality at 48 h post-infection.
  • Vp inoculum 60 mL was added to each challenge tank. Then the shrimp were monitored for survival every 3 h up to 187 h by which point the mortalities had stabilised. At 24 h, a further 7.5 L of 15 ppt seawater was added to each tank and the shrimp were maintained on their respective diets. At 48 h and 72 h, 5 L of tank water was removed and replaced.
  • Cluster A comprised 100 shrimp divided into 5 replicates of 10 shrimp per tank representing the challenge group, and then a further 5 replicates of 10 shrimp per tank representing the non- challenged group.
  • Cluster B consisted of 50 shrimp which were used for the sampling of haemocytes on days 1, 3, 5 and 7 days’ post-challenge.
  • a second 10 microlitre sample was transferred to a clean microscope slide and a smear was prepared. After air drying, the smears were then counterstained with a haemotoxylin solution for 7-10 min, then rinsed in tap water for 10 min and then dehydrated in 95% ethanol (10 dips) and then in 100% etha nol (10 dips). The preparations were then dehydrated by immersion in xylene, 3 x 3 min and then coverslipped. The proportion of granulocytes was determined from a count of 200 haemocytes and then the total number was recorded by using this proportion and multiply ing it by the total number of haemocytes (i.e. count/200 x THC).
  • Table 13 The corrected total haemocyte counts (THC) from shrimp experimental chal lenged with a pathogenic isolate of Vibrio parahaemolyticus causing AHPND at different time points post-challenge.
  • Table 14 The total number of granulocytes in samples taken from whiteleg shrimp at differ ent time points following their experimental challenge with a pathogenic isolate of Vibrio parahaemolyticus causing AHPND. The counts were calculated using the percentage granu locyte count and the total haemocyte count
  • the final FCRs were higher than the 1.2 expected by the study monitor and were 1.37-1.73 for the three DSM formulated diets (in a rank order of Diet 2, 3 and 1).
  • the shrimp fed Diet 2 had statistically higher rates of survival (74% versus 34% for Diet 1 and 32% for Diet 3).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Birds (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)

Abstract

La présente invention concerne l'utilisation de vitamine C et de vitamine E en combinaison avec un bêta-glucane et/ou des nucléotides, dans la fabrication d'une composition alimentaire pour animaux aquatiques, notamment pour poissons d'eaux froides comme, par exemple, le saumon, la brème, le bar, ainsi que pour poissons d'eaux chaudes comme, par exemple, les crevettes, la carpe, le tilapia, le poisson-chat.
PCT/EP2019/061906 2018-05-09 2019-05-09 Complément alimentaire et son utilisation pour animaux aquatiques WO2019215276A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18171403.1 2018-05-09
EP18171403 2018-05-09

Publications (1)

Publication Number Publication Date
WO2019215276A1 true WO2019215276A1 (fr) 2019-11-14

Family

ID=62148138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/061906 WO2019215276A1 (fr) 2018-05-09 2019-05-09 Complément alimentaire et son utilisation pour animaux aquatiques

Country Status (1)

Country Link
WO (1) WO2019215276A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111700186A (zh) * 2020-06-11 2020-09-25 上海牧高生物科技有限公司 一种提高鱼虾免疫力的复合预混料及其制备方法
CN114732093A (zh) * 2022-04-24 2022-07-12 江苏海洋大学 一种淡水甲壳动物用复合免疫增强剂及其应用方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000035A1 (fr) * 2000-06-23 2002-01-03 Acuabiotec Llc Complexe alimentaire bioactif, procede servant a preparer un complexe alimentaire bioactif et procede servant a lutter contre les maladies
WO2004043139A2 (fr) * 2002-11-14 2004-05-27 Advanced Bionutrition Corp. Nourriture adaptee pour la culture de rotiferes, de larves de crevettes et d'autres organismes filtreurs marins
WO2004091307A2 (fr) 2003-04-08 2004-10-28 Advanced Bionutriton Corporation Additifs alimentaires destines a proteger des animaux terrestres et aquatiques contre une infection pathologique
CN103027202A (zh) * 2012-12-11 2013-04-10 青岛恒生源生态农业有限公司 一种稚参养殖全价饲料
CN104397433A (zh) * 2014-12-10 2015-03-11 苏州埃瑞特生物技术有限公司 一种对虾促免疫增强剂的研制
CN104872456A (zh) * 2015-06-17 2015-09-02 广东通威饲料有限公司 草鱼、罗非鱼亲鱼通用型配合饲料及其制备方法
DE102014104335A1 (de) * 2014-03-27 2015-10-01 Aqua Schwarz Gmbh Aquaorganismus-Futtermittel und Verwendung desselben
CN105851490A (zh) * 2016-06-17 2016-08-17 安庆市皖宜季牛水产养殖有限责任公司 一种增强免疫力的青虾幼体饲料

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000035A1 (fr) * 2000-06-23 2002-01-03 Acuabiotec Llc Complexe alimentaire bioactif, procede servant a preparer un complexe alimentaire bioactif et procede servant a lutter contre les maladies
WO2004043139A2 (fr) * 2002-11-14 2004-05-27 Advanced Bionutrition Corp. Nourriture adaptee pour la culture de rotiferes, de larves de crevettes et d'autres organismes filtreurs marins
WO2004091307A2 (fr) 2003-04-08 2004-10-28 Advanced Bionutriton Corporation Additifs alimentaires destines a proteger des animaux terrestres et aquatiques contre une infection pathologique
CN103027202A (zh) * 2012-12-11 2013-04-10 青岛恒生源生态农业有限公司 一种稚参养殖全价饲料
DE102014104335A1 (de) * 2014-03-27 2015-10-01 Aqua Schwarz Gmbh Aquaorganismus-Futtermittel und Verwendung desselben
CN104397433A (zh) * 2014-12-10 2015-03-11 苏州埃瑞特生物技术有限公司 一种对虾促免疫增强剂的研制
CN104872456A (zh) * 2015-06-17 2015-09-02 广东通威饲料有限公司 草鱼、罗非鱼亲鱼通用型配合饲料及其制备方法
CN105851490A (zh) * 2016-06-17 2016-08-17 安庆市皖宜季牛水产养殖有限责任公司 一种增强免疫力的青虾幼体饲料

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111700186A (zh) * 2020-06-11 2020-09-25 上海牧高生物科技有限公司 一种提高鱼虾免疫力的复合预混料及其制备方法
CN114732093A (zh) * 2022-04-24 2022-07-12 江苏海洋大学 一种淡水甲壳动物用复合免疫增强剂及其应用方法

Similar Documents

Publication Publication Date Title
Skjermo et al. The effect of microalgae on skin and gut bacterial flora of halibut larvae
Suzer et al. Lactobacillus spp. bacteria as probiotics in gilthead sea bream (Sparus aurata, L.) larvae: effects on growth performance and digestive enzyme activities
Tacchi et al. Transcriptomic responses to functional feeds in Atlantic salmon (Salmo salar)
McIntosh et al. Culture-independent characterization of the bacterial populations associated with cod (Gadus morhua L.) and live feed at an experimental hatchery facility using denaturing gradient gel electrophoresis
Dash et al. The addition of probiotic bacteria to microbial floc: Water quality, growth, non-specific immune response and disease resistance of Cyprinus carpio in mid-Himalayan altitude
Makled et al. Growth promotion and immune stimulation in Nile tilapia, Oreochromis niloticus, fingerlings following dietary administration of a novel marine probiotic, Psychrobacter maritimus S
Fernandez et al. Effect of lactic acid bacteria administered orally on growth performance of Penaeus indicus (H. Milne Edwards) juveniles
Lauzon et al. Effects of bacterial treatment at early stages of Atlantic cod (Gadus morhua L.) on larval survival and development
Saad et al. Growth response of the freshwater prawn, Macrobrachium rosenbergii (De Man), to diets having different levels of Biogen®
Lauzon et al. Probiotic applications in cold water fish species
Mohammadian et al. Effect of different levels of dietary acidifier “sodium diformate” on the innate immune system and expression of growth and immunological related genes in Salmo trutta caspius
Can et al. The use of kefir as potential probiotic in Çoruh trout (Salmo coruhensis): Effects on growth performance and immunoglobulin (IgM) levels
Sun et al. Microbial communities associated with early stages of intensively reared orange‐spotted grouper (E pinephelus coioides)
Wasana et al. Probiotic effects of Pseudoalteromonas ruthenica: Antibacterial, immune stimulation and modulation of gut microbiota composition
WO2019215276A1 (fr) Complément alimentaire et son utilisation pour animaux aquatiques
Toutou et al. Effect of probiotic and synbiotic food supplementation on growth performance and healthy status of grass carp, Ctenopharyngodon idella (Valenciennes, 1844)
Onianwah et al. Microorganisms in sustainable aquaculture development
Dosta et al. Bacteria with probiotic capabilities isolated from the digestive tract of the ornamental fish Pterophyllum scalare
Hassanien et al. Physiological and haematological responses of the Nile tilapia (Oreochromis niloticus) fed on diets supplemented with probiotics
Loh et al. Effects of Artemia nauplii bioencapsulated with Lactococcus lactis subsp. lactis CF4MRS and sodium alginate on edwardsiellosis protection and digestive enzyme production in climbing perch larvae, Anabas testudineus (Bloch, 1792)
Dahiya Applications and possible modes of action of probiotics in aquaculture
Alavinejad et al. Effect of dietary supplementation of potential probiotic Lacticaseibacillus casei on immune-related genes expression, intestinal microbiota and gut histology of zebrafish (Danio rerio) during Aeromonas hydrophila infection
Das et al. Effect of feed probiotic on the growth and their colonization performance on the intestine of rohu (Labeo rohita)
SAHANDI et al. Effect of possible probiotic strains on suppression of Vibrio and enhancement of growth in rotifer, Brachionus plicatilis
Jinia et al. Effect of probiotics on growth, feed utilization and whole-body proximate composition of pabda (Ompok pabda) juvenile

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19723094

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19723094

Country of ref document: EP

Kind code of ref document: A1